Cardiovascular Biomarkers after Metabolic Surgery versus Medical Therapy for Diabetes: Insights from the STAMPEDE Trial

Background: Longitudinal studies have shown that bariatric and metabolic surgery is associated with significant reduction in cardiovascular events and mortality. The Surgical Treatment And Medications Potentially Eradicate Diabetes Efficiently (STAMPEDE) trial showed that 5-years after randomization, Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) were superior to intensive medical therapy (IMT) alone in achieving glycemic control in patients with type 2 diabetes mellitus (T2DM). The aim of this study was to assess long-term changes in cardiovascular biomarkers after surgical versus medical treatment of T2DM.